CARLSBAD, Calif., April 6 /PRNewswire/ -- RoboDesign International, Inc., announced that the Structural Genomics Consortium (SGC) has chosen CrystalMation(TM) as its standard protein crystal imaging and analysis technology. CrystalMation is a fully modular and automated protein crystallization platform, which includes systems for liquid handling, low volume dispense, imaging, storage and analysis.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030603/ROBODESIGNLOGO)
The SGC will be utilizing the Minstrel III and RoboIncubator combinations for its high throughput crystallography facility. With its high-resolution imaging system, programmable lighting system, and RoboDesign's patent-pending image processing method, the Minstrel III was specifically designed to address the unique challenges to protein drop imaging. As with all of the CrystalMation components, the Minstrel III was designed to be expandable and modular. It can be expanded with multiple RoboIncubators and a wide array of software tools. Delivery of the first systems to the University of Oxford will be in May 2004.
"We are pleased and excited to support the SGC through the installation of CrystalMation," said Robert L. Corey, president and CEO of RoboDesign. "The SGC's goal of determining 200 protein structures per year absolutely requires automation that can address the bottlenecks associated with traditional methods of crystallization. We believe that our CrystalMation platform does just that by revolutionizing the way and speed in which crystallization is performed."
About RoboDesign(R) International Inc.
RoboDesign International, Inc. is a premier source for the development, design, and manufacture of automation solutions and instrumentation for the life sciences industry. RoboDesign offers standard as well as custom products for drug discovery, laboratory and hospital automation. In addition, with its broad range of technical expertise, RoboDesign is uniquely positioned to provide a wide array of engineering services, from rapid prototyping to OEM design and manufacturing. From fully automated pharmacy systems to protein crystal imaging and analysis, RoboDesign's enabling technologies are playing a vital role in all phases of the fight against disease.
About Structural Genomics Consortium
SGC is a not-for-profit organization that aims to determine the three dimensional structures of proteins of medical relevance, and place them in the public domain without restriction. The goal is to develop the infrastructure and technologies necessary for rapid, parallel, structure determination, with the aim of having the capability to determine 200 protein structures per year. The structural information generated by SGC is expected to have a tremendous impact on human health by furthering the understanding of relevant proteins and by supplying new targets for therapeutic interventions. It will also provide the structural framework for the rational design of new or improved drugs that can inhibit or enhance protein function.
For further information, please contact Tommy Bui, Director of Business Development of RoboDesign International, Inc., +1-760-438-5282, info@robodesign.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20030603/ROBODESIGNLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comRoboDesign International, Inc.CONTACT: Tommy Bui, Director of Business Development of RoboDesignInternational, Inc., +1-760-438-5282, info@robodesign.com
Web site: http://www.robodesign.com/
